Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1526MR)

This product GTTS-WQ1526MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1526MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4839MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ2360MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ1473MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ472MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ3937MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ12416MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ3985MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ11987MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-121
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW